ATE210652T1 - Tricyclische carbamat-derivate zur inhibierung der g-protein funktion und für die behandlung von proliferativen erkrankungen - Google Patents

Tricyclische carbamat-derivate zur inhibierung der g-protein funktion und für die behandlung von proliferativen erkrankungen

Info

Publication number
ATE210652T1
ATE210652T1 AT94930074T AT94930074T ATE210652T1 AT E210652 T1 ATE210652 T1 AT E210652T1 AT 94930074 T AT94930074 T AT 94930074T AT 94930074 T AT94930074 T AT 94930074T AT E210652 T1 ATE210652 T1 AT E210652T1
Authority
AT
Austria
Prior art keywords
inhibiting
carbamat
tricyclic
derivatives
treatment
Prior art date
Application number
AT94930074T
Other languages
German (de)
English (en)
Inventor
W Robert Bishop
Ronald J Doll
Alan K Mallams
F George Njoroge
Joanne M Petrin
John J Piwinski
Stacy W Remiszewski
Arthur G Taveras
Ronald L Wolin
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE210652T1 publication Critical patent/ATE210652T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
AT94930074T 1993-10-15 1994-10-12 Tricyclische carbamat-derivate zur inhibierung der g-protein funktion und für die behandlung von proliferativen erkrankungen ATE210652T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13743593A 1993-10-15 1993-10-15
PCT/US1994/011391 WO1995010515A1 (en) 1993-10-15 1994-10-12 Tricyclic carbamate compounds useful for inhibition of g-protein function and for treatment of proliferative diseases

Publications (1)

Publication Number Publication Date
ATE210652T1 true ATE210652T1 (de) 2001-12-15

Family

ID=22477422

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94930074T ATE210652T1 (de) 1993-10-15 1994-10-12 Tricyclische carbamat-derivate zur inhibierung der g-protein funktion und für die behandlung von proliferativen erkrankungen

Country Status (18)

Country Link
EP (1) EP0723538B1 (show.php)
JP (1) JP2875393B2 (show.php)
AT (1) ATE210652T1 (show.php)
AU (1) AU699043B2 (show.php)
CA (1) CA2174105C (show.php)
DE (1) DE69429438T2 (show.php)
DK (1) DK0723538T3 (show.php)
ES (1) ES2164716T3 (show.php)
HU (1) HUT76066A (show.php)
IL (1) IL111258A0 (show.php)
MA (1) MA23353A1 (show.php)
NZ (1) NZ274749A (show.php)
PT (1) PT723538E (show.php)
SG (1) SG48750A1 (show.php)
TN (1) TNSN94104A1 (show.php)
TW (1) TW308594B (show.php)
WO (1) WO1995010515A1 (show.php)
ZA (1) ZA947970B (show.php)

Families Citing this family (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0703905A1 (en) * 1993-06-18 1996-04-03 Merck & Co. Inc. Inhibitors of farnesyl-protein transferase
JP2875392B2 (ja) 1993-10-15 1999-03-31 シェーリング コーポレイション Ｇ−タンパク質機能の阻害および増殖性疾患の治療に有用な三環式スルホンアミド化合物
US5721236A (en) * 1993-10-15 1998-02-24 Schering Corporation Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US6524832B1 (en) 1994-02-04 2003-02-25 Arch Development Corporation DNA damaging agents in combination with tyrosine kinase inhibitors
US5700806A (en) * 1995-03-24 1997-12-23 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5856326A (en) * 1995-03-29 1999-01-05 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5712280A (en) * 1995-04-07 1998-01-27 Schering Corporation Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
IL117798A (en) * 1995-04-07 2001-11-25 Schering Plough Corp Tricyclic compounds useful for inhibiting the function of protein - G and for the treatment of malignant diseases, and pharmaceutical preparations containing them
IL117797A0 (en) * 1995-04-07 1996-08-04 Pharmacopeia Inc Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5801175A (en) * 1995-04-07 1998-09-01 Schering Corporation Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
CA2226623A1 (en) * 1995-07-13 1997-01-30 University Of Cincinnati Compounds useful in the treatment of neurofibromatosis
US5874442A (en) * 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
WO1997023478A1 (en) * 1995-12-22 1997-07-03 Schering Corporation Tricyclic amides useful for inhibition of g-protein function and for treatment of proliferative diseases
US6028201A (en) * 1996-01-30 2000-02-22 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
AU6605196A (en) * 1996-02-29 1997-09-16 Duke University Method of treating hepatitis delta virus infection
DE19624659A1 (de) 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalken- und Pyridylalkinsäureamide
US6451816B1 (en) 1997-06-20 2002-09-17 Klinge Pharma Gmbh Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression
US5925757A (en) * 1996-07-26 1999-07-20 Schering Corporation Method for preparing carboxamides
PE92098A1 (es) * 1996-07-31 1998-12-31 Schering Corp N-cianoiminas triciclicas utiles como inhibidores de transferasa de proteina farnesilo
CZ84199A3 (cs) * 1996-09-13 1999-11-17 Schering Corporation Nové, tricyklické piperidinylové sloučeniny použitelné jako inhibitory farnesylprotein transferasy
US5945429A (en) * 1996-09-13 1999-08-31 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6030982A (en) * 1996-09-13 2000-02-29 Schering Corporationm Compounds useful for inhibition of farnesyl protein transferase
US5994364A (en) * 1996-09-13 1999-11-30 Schering Corporation Tricyclic antitumor farnesyl protein transferase inhibitors
BR9712035A (pt) * 1996-09-13 1999-08-24 Schering Corp Compostos Úteis para inibi-Æo de transferase de prote¡na farnesila
US6040305A (en) * 1996-09-13 2000-03-21 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
KR20000036111A (ko) * 1996-09-13 2000-06-26 둘락 노먼 씨. 파네실 단백질 트랜스페라제 억제제인 트리사이클릭 항종양성화합물
JP2001500510A (ja) * 1996-09-13 2001-01-16 シェーリング コーポレイション ファルネシルタンパク質トランスフェラーゼの三環系インヒビター
US5985879A (en) * 1996-09-13 1999-11-16 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US5861395A (en) * 1996-09-13 1999-01-19 Schering Corporation Compounds useful for inhibition of farnesyl proteins transferase
US6071907A (en) * 1996-09-13 2000-06-06 Schering Corporation Tricyclic compounds useful as FPT inhibitors
DE69710741T2 (de) * 1996-09-13 2002-10-24 Schering Corp., Kenilworth Tricyclische verbindungen zur inhibierung der g-protein funktion und für die behandlung von proliferativen erkrankungen
US5958890A (en) * 1996-09-13 1999-09-28 Schering Corporation Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
ATE286044T1 (de) * 1996-09-13 2005-01-15 Schering Corp Trizyklische verbindungen mit farnesyl protein transferase inhibierender wirkung
US5965570A (en) * 1996-09-13 1999-10-12 Schering Corporation Tricyclic piperidinyl compounds useful as inhibitors of farnesyl-protein transferase
DE69733142T2 (de) * 1996-09-13 2006-03-16 Schering Corp. Substituierte benzocycloheptapyridine derivate verwendbar als farnesyl-protein transferase inhibitoren
JP2001505189A (ja) * 1996-10-09 2001-04-17 シェーリング コーポレイション Ｒａｓ―ＦＰＴインヒビターとしての活性を有する三環式化合物
US6130229A (en) * 1996-10-09 2000-10-10 Schering Corporation Tricyclic compounds having activity as RAS-FPT inhibitors
US5760232A (en) * 1997-06-16 1998-06-02 Schering Corporation Synthesis of intermediates useful in preparing bromo-substituted tricyclic compounds
KR20010013825A (ko) * 1997-06-17 2001-02-26 둘락 노먼 씨. 파네실 단백질 전이효소를 억제하기에 유용한비스피리도-사이클로헵탄 화합물
KR20010013945A (ko) * 1997-06-17 2001-02-26 둘락 노먼 씨. 파르네실-단백질 트랜스퍼라제의 신규한 페닐-치환된트리사이클릭 억제제
US5925639A (en) * 1997-06-17 1999-07-20 Schering Corporation Keto amide derivatives useful as farnesyl protein transferase inhibitors
US6576639B1 (en) 1997-06-17 2003-06-10 Schering Corporation Compounds for the inhibition of farnesyl protein transferase
US6689789B2 (en) 1997-06-17 2004-02-10 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US5877177A (en) * 1997-06-17 1999-03-02 Schering Corporation Carboxy piperidylacetamide tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US6239140B1 (en) 1997-06-17 2001-05-29 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
AU8253498A (en) * 1997-06-17 1999-01-04 Schering Corporation Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
KR20010013953A (ko) * 1997-06-17 2001-02-26 둘락 노먼 씨. 파네실 단백질 트랜스퍼라제의 억제에 유용한 화합물
CA2293373C (en) * 1997-06-17 2008-09-23 Schering Corporation Benzo(5,6)cyclohepta(1,2b)pyridine derivatives useful for inhibition of farnesyl protein transferase
US6159984A (en) * 1997-06-17 2000-12-12 Schering Corporation Farnesyl protein transferase inhibitors
US6051582A (en) * 1997-06-17 2000-04-18 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6218401B1 (en) 1997-06-17 2001-04-17 Schering Corporation Phenyl-substituted tricyclic inhibitors of farnesyl-protein transferase
US6225322B1 (en) 1997-06-17 2001-05-01 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
PE104798A1 (es) * 1997-06-17 1999-11-06 Pharmacopeia Inc Compuestos utiles para la inhibicion de la enzima farnesilo transferasa
US6211193B1 (en) 1997-06-17 2001-04-03 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6228865B1 (en) 1997-06-17 2001-05-08 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US5925648A (en) * 1997-07-29 1999-07-20 Schering Corporation Tricyclic N-cyanoimines useful as inhibitors of a farnesyl-protein transferase
US5958940A (en) * 1997-09-11 1999-09-28 Schering Corporation Tricyclic compounds useful as inhibitors of farnesyl-protein transferase
WO1999019322A1 (en) * 1997-10-10 1999-04-22 Schering Corporation ETHYL 4-(8-CHLORO-5, 6-DIHYDRO-11H- BENZO[5,6]CYCLOHEPTA [1,2-b]PYRIDIN -11-YLIDENE)-1- PIPERIDENE CARBOXYLATE POLYMORPH
DE19756261A1 (de) 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue arylsubstituierte Pyridylalkan-, alken- und alkincarbonsäureamide
DE19756235A1 (de) 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue piperidinylsubstituierte Pyridylalkan- alken- und -alkincarbonsäureamide
US6903118B1 (en) 1997-12-17 2005-06-07 Klinge Pharma Gmbh Piperazinyl-substituted pyridylalkane, alkene and alkine carboxamides
DE19756212A1 (de) * 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue, mit einem cyclischen Imid substituierte Pyridylalkan-, alken- und -alkincarbonsäureamide
US6632455B2 (en) 1997-12-22 2003-10-14 Schering Corporation Molecular dispersion composition with enhanced bioavailability
WO2000001382A1 (en) 1998-07-02 2000-01-13 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
EP1090011A4 (en) 1998-07-02 2005-04-06 Merck & Co Inc INHIBITORS OF PRENYL-PROTEIN TRANSFERASE
US6372747B1 (en) 1998-12-18 2002-04-16 Schering Corporation Farnesyl protein transferase inhibitors
EP1031564A1 (en) 1999-02-26 2000-08-30 Klinge Pharma GmbH Inhibitors of cellular nicotinamide mononucleotide formation and their use in cancer therapy
PE20001566A1 (es) 1999-03-26 2001-02-05 Ucb Sa Piperazinas 1,4-sustituidas, piperidinas 1,4-sustituidas y 4-alquilidenilpiperidinas 1-sustituidas
US6686502B1 (en) 1999-03-26 2004-02-03 Ucb S.A. Compounds and methods for treatment of asthma, allergy and inflammatory disorders
US6316462B1 (en) 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
EP1214326A1 (en) * 1999-09-09 2002-06-19 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US7074921B2 (en) 2001-11-13 2006-07-11 Bristol Myers Squibb Company Process for the preparation of 3,7-disubstituted-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine compounds
EP1507531B1 (en) * 2003-03-12 2007-01-24 Teva Pharmaceutical Industries Ltd Stable pharmaceutical compositions of desloratadine
WO2005017160A2 (en) 2003-08-13 2005-02-24 Children's Hospital Medical Center Mobilization of hematopoietic cells
ES2382814T3 (es) 2005-05-17 2012-06-13 Merck Sharp & Dohme Ltd. Ácido cis-4-[(4-clorofenil)sulfonil]-4-(2,5-difluorofenil)ciclohexanopropanoico para el tratamiento del cáncer
PE20070335A1 (es) 2005-08-30 2007-04-21 Novartis Ag Benzimidazoles sustituidos y metodos para su preparacion
WO2007050383A2 (en) * 2005-10-21 2007-05-03 Merck & Co., Inc. Tyrosine kinase inhibitors
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
JP5328640B2 (ja) 2006-04-19 2013-10-30 ノバルティス アーゲー ６−ｏ−置換ベンゾオキサゾールおよびベンゾチアゾール化合物ならびにｃｓｆ−１ｒシグナル伝達を阻害する方法
EP2083831B1 (en) 2006-09-22 2013-12-25 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
SI2805945T1 (sl) 2007-01-10 2019-09-30 Msd Italia S.R.L. Amid substituirani indazoli, kot inhibitorji poli(ADP-riboza)polimeraze(PARP)
MX2009009304A (es) 2007-03-01 2009-11-18 Novartis Ag Inhibidores de cinasa pim y metodos para su uso.
CN101754965B (zh) 2007-05-21 2014-03-19 诺华股份有限公司 Csf-1r抑制剂、组合物及使用方法
JP5501227B2 (ja) 2007-06-27 2014-05-21 メルク・シャープ・アンド・ドーム・コーポレーション ヒストンデアセチラーゼ阻害剤としての４−カルボキシベンジルアミノ誘導体
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
CN102480966B (zh) 2009-06-12 2015-09-16 达娜-法勃肿瘤研究所公司 融合的杂环化合物及其用途
AU2010307198B9 (en) 2009-10-14 2014-02-13 Merck Sharp & Dohme Corp. Substituted piperidines that increase p53 activity and the uses thereof
WO2011090738A2 (en) 2009-12-29 2011-07-28 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
KR20130006664A (ko) 2010-03-16 2013-01-17 다나-파버 캔서 인스티튜트 인크. 인다졸 화합물 및 그의 용도
US8999957B2 (en) 2010-06-24 2015-04-07 Merck Sharp & Dohme Corp. Heterocyclic compounds as ERK inhibitors
WO2012018754A2 (en) 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
DK2606134T3 (da) 2010-08-17 2019-07-22 Sirna Therapeutics Inc RNA-Interferens-formidlet inhibering af hepatitis-B-virus (HBV)-genekspression ved hjælp af kort interfererende nukleinsyre (siNA)
EP2608669B1 (en) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
WO2012036997A1 (en) 2010-09-16 2012-03-22 Schering Corporation Fused pyrazole derivatives as novel erk inhibitors
ES2663009T3 (es) 2010-10-29 2018-04-10 Sirna Therapeutics, Inc. Inhibición de la expresión génica mediada por interferencia por ARN utilizando ácidos nucleicos de interferencia cortos (ANic)
EP2654748B1 (en) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
CA2831730A1 (en) 2011-04-21 2012-10-26 Piramal Enterprises Limited A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
WO2013063214A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP3569598A1 (en) 2011-11-17 2019-11-20 Dana Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
WO2013165816A2 (en) 2012-05-02 2013-11-07 Merck Sharp & Dohme Corp. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
CA2882950A1 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
WO2014063068A1 (en) 2012-10-18 2014-04-24 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2014063061A1 (en) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
WO2014063054A1 (en) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof
AU2013352568B2 (en) 2012-11-28 2019-09-19 Merck Sharp & Dohme Llc Compositions and methods for treating cancer
ES2707305T3 (es) 2012-12-20 2019-04-03 Merck Sharp & Dohme Imidazopiridinas sustituidas como inhibidores de HDM2
US9540377B2 (en) 2013-01-30 2017-01-10 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as HDM2 inhibitors
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
JP6491202B2 (ja) 2013-10-18 2019-03-27 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド サイクリン依存性キナーゼ７（ｃｄｋ７）の多環阻害剤
WO2015058126A1 (en) 2013-10-18 2015-04-23 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of prolferative diseases
WO2015164614A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
WO2015164604A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
US10870651B2 (en) 2014-12-23 2020-12-22 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
JP6861166B2 (ja) 2015-03-27 2021-04-21 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼの阻害剤
AU2016276963C1 (en) 2015-06-12 2021-08-05 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
EP3347018B1 (en) 2015-09-09 2021-09-01 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
JOP20190055A1 (ar) 2016-09-26 2019-03-24 Merck Sharp & Dohme أجسام مضادة ضد cd27
EP3525785B1 (en) 2016-10-12 2025-08-27 Merck Sharp & Dohme LLC Kdm5 inhibitors
TW202430219A (zh) 2017-04-13 2024-08-01 荷蘭商賽羅帕公司 抗-SIRPα 抗體
EP3706742B1 (en) 2017-11-08 2023-03-15 Merck Sharp & Dohme LLC Prmt5 inhibitors
US11098059B2 (en) 2017-11-08 2021-08-24 Merck Sharp & Dohme Corp. PRMT5 inhibitors
WO2019148412A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
AU2019295632B2 (en) 2018-06-25 2025-03-06 Dana-Farber Cancer Institute, Inc. Taire family kinase inhibitors and uses thereof
US11993602B2 (en) 2018-08-07 2024-05-28 Merck Sharp & Dohme Llc PRMT5 inhibitors
WO2020033284A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
JP7446282B2 (ja) 2018-08-07 2024-03-08 メルク・シャープ・アンド・ドーム・エルエルシー Ｐｒｍｔ５阻害剤
US12281126B2 (en) 2018-12-28 2025-04-22 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 and uses thereof
EP4076460A4 (en) 2019-12-17 2023-11-15 Merck Sharp & Dohme LLC PRMT5 INHIBITORS
IL322769A (en) 2023-03-02 2025-10-01 Carcimun Biotech Gmbh Means and methods for diagnosing cancer and/or acute inflammatory disease
CN116496259B (zh) * 2023-04-24 2025-08-29 黑龙江珍宝岛药业股份有限公司 一种富马酸卢帕他定的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4282233B1 (en) * 1980-06-19 2000-09-05 Schering Corp Antihistaminic 11-(4-piperidylidene)-5h-benzoÄ5,6Ü-cyclohepta-Ä1,2Ü-pyridines
US4826853A (en) * 1986-10-31 1989-05-02 Schering Corporation 6,11-Dihydro-11-(N-substituted-4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-B)pyridines and compositions and methods of use
US4863931A (en) * 1988-09-15 1989-09-05 Schering Corporation Antihistaminic fluoro substituted benzocycloheptapyridines
JPH06504772A (ja) * 1990-12-18 1994-06-02 ザ　ウエルカム　ファウンデーション　リミテッド 抗癌剤の薬効を増強し抗多剤耐性を有する薬剤

Also Published As

Publication number Publication date
CA2174105A1 (en) 1995-04-20
JPH08510759A (ja) 1996-11-12
TNSN94104A1 (fr) 1995-09-21
TW308594B (show.php) 1997-06-21
CA2174105C (en) 2002-02-12
IL111258A0 (en) 1994-12-29
ES2164716T3 (es) 2002-03-01
JP2875393B2 (ja) 1999-03-31
PT723538E (pt) 2002-05-31
DE69429438D1 (de) 2002-01-24
SG48750A1 (en) 1998-05-18
ZA947970B (en) 1996-07-12
AU699043B2 (en) 1998-11-19
MA23353A1 (fr) 1995-07-01
HUT76066A (en) 1997-06-30
EP0723538B1 (en) 2001-12-12
DE69429438T2 (de) 2002-08-08
WO1995010515A1 (en) 1995-04-20
DK0723538T3 (da) 2002-03-18
EP0723538A1 (en) 1996-07-31
HU9600963D0 (en) 1996-06-28
AU7930994A (en) 1995-05-04
NZ274749A (en) 1998-05-27

Similar Documents

Publication Publication Date Title
ATE210652T1 (de) Tricyclische carbamat-derivate zur inhibierung der g-protein funktion und für die behandlung von proliferativen erkrankungen
DE69429440D1 (de) Tricyclische sulfonamide-derivate zur inhibierung der g-protein funktion und fur die bekandlung von proliferativen erkrantungen
DE69434397D1 (de) Tricyclische Amide und Harnstoffderivate zur Inhibierung der G-Protein Funktion und für die Behandlung von proliferativen Behandlungen
MX9707192A (es) Compuestos triciclicos de carbamato, utiles para la inhibicion de la funcion de la proteina g y paratratamiento de enfermedades proliferativas.
CS38989A2 (en) Method of phenoxyacetamidoderivative production
DE69427517D1 (de) Tetracyclische kondensierte heterocyclische Verbindungen zur Behandlung von seniler Demenz
DE69710741D1 (de) Tricyclische verbindungen zur inhibierung der g-protein funktion und für die behandlung von proliferativen erkrankungen
ATE196734T1 (de) Zusammensetzungen von ergolinderivaten zur behandlung des glaukoms
BG103271A (en) Derivatives of n-(benzothiazol-2-yl) piperidine-1-ethaneamines, method for their preparation and application as therapeutical means
ATE237611T1 (de) Cyclische harnstoff- und lactamderivate von benzo(5,6)cycloheptapyridinen zur verwendung als farnesyl-protein-transferase-hemmer
ATE231141T1 (de) (-)-enantiomere von cis-3,4-chromanderivaten zur vorbeugung oder behandlungvon oestrogenbezogenen krankheiten oder syndromen
DE69619088D1 (de) Quinoxalin-Derivate zur Behandlung von Tinnitus
DZ1704A1 (fr) Dérivés de la n-(phényléthyl-b-ol) amine ainsi queleur procédé de préparation.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee